Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Apple Turns 50: From Garage Startup to AI Crossroads 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Britain Courts Anthropic Amid US Defense Department Dispute 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
STAMFORD, Conn., Nov. 22, 2016 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will participate in a fireside chat at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016, at 4:30 p.m. ET in New York City.
A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations, Inc. 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
